Medications for Weight Loss and MASLD

医学 减肥 内科学 肥胖
作者
Gene Y. Im,Amon Asgharpour,Elizabeth S. Aby,Jonathan G. Stine,Jessica L. Mellinger,Jay Luther,Manhal Izzy,Lamia Haque,Brian T. Lee,Thomas G. Cotter,Courtney B. Sherman,Loretta Jophlin,Aparna Goel,John P. Rice,Shaun Chandna,Blanca Lizaola‐Mayo,Po‐Hung Chen,Ashwani K. Singal,Meena B. Bansal
出处
期刊:Journal of Clinical Gastroenterology [Lippincott Williams & Wilkins]
被引量:1
标识
DOI:10.1097/mcg.0000000000002147
摘要

Our aim was to perform a national survey of provider attitudes, practices, and knowledge regarding weight loss and MASLD medications in patients with MASLD. While weight loss is a cornerstone in the management of metabolic dysfunction-associated steatotic liver disease (MASLD), FDA-approved medications for weight loss remain underutilized. We conducted a survey before resmetirom approval of hepatology and gastroenterology providers practicing in 44 states. Surveys were sent to 747 providers with 304 complete responses (41%), of whom 260 (86%) work at a liver transplant center. While nearly all respondents (96%) believed that weight loss medications could benefit patients with MASLD, 77% have never/rarely prescribed them due to low comfort (81%). Among weight loss medication prescribers, glucagon-like peptide-1 (GLP-1) receptor agonists were preferred (66%). In contrast, 63% had prescribed off-label medications for MASLD in the past 12 months, most commonly vitamin E (30%) and GLP-1 receptor agonists (25%). The top reported barriers to prescribing weight loss medications were lack of training/unfamiliarity, cost/insurance coverage, and side-effects, which may be explained by low formal obesity education and lack of knowledge (only 33% of FDA-approved medications for weight loss were correctly identified by >50% of providers). Overall, there was reasonable provider-reported adherence to the 2023 AASLD practice guidance for MASLD. This nationwide survey of hepatology and gastroenterology providers before resmetirom demonstrates that while off-label prescribing for MASLD was common, weight loss medication prescription rates remain very low due to low comfort possibly from insufficient education despite strong beliefs that they can benefit patients with MASLD.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
要减肥听云完成签到,获得积分10
1秒前
2秒前
theverve发布了新的文献求助30
2秒前
朝颜完成签到,获得积分10
3秒前
挚友发布了新的文献求助10
4秒前
4秒前
大力凤凰完成签到,获得积分20
5秒前
5秒前
wwq完成签到,获得积分20
6秒前
无私的刘关注了科研通微信公众号
6秒前
超级拖延症完成签到 ,获得积分10
6秒前
乐乐的应助被chenjunhuan采纳,获得10
6秒前
7秒前
www发布了新的文献求助10
8秒前
8秒前
我想想完成签到,获得积分10
9秒前
9秒前
NexusExplorer的应助被Lee采纳,获得10
9秒前
darling完成签到,获得积分10
9秒前
10秒前
桐桐的应助被anyanjiao采纳,获得50
10秒前
无知小白发布了新的文献求助10
11秒前
上官若男的应助被花开四海采纳,获得10
12秒前
每日早睡完成签到 ,获得积分10
13秒前
zkj1989发布了新的文献求助10
13秒前
彭于晏的应助被科研通管家采纳,获得10
14秒前
小二郎的应助被科研通管家采纳,获得10
14秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
14秒前
wang完成签到,获得积分10
14秒前
顾矜的应助被科研通管家采纳,获得10
14秒前
14秒前
null的应助被科研通管家采纳,获得10
15秒前
充电宝的应助被科研通管家采纳,获得30
15秒前
15秒前
秋风的应助被科研通管家采纳,获得20
15秒前
爆米花的应助被壮观雁易采纳,获得10
15秒前
大模型的应助被科研通管家采纳,获得10
15秒前
15秒前
朱琳完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158056
求助须知:如何正确求助?哪些是违规求助? 9553944
关于积分的说明 21716733
捐赠科研通 7747388
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471038